<DOC>
	<DOC>NCT00851344</DOC>
	<brief_summary>A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis</brief_summary>
	<brief_title>Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Subject is healthy apart from seasonal allergic rhinitis, as determined by a physician. Can have mild asthma. Male Aged 18 60 Weight 50kg+, BMI 1932 kg/m2 Exhibit response to Challenge Chamber and skin prick test. Nonsmoker Capable of giving informed consent No nasal structural abnornmality/polyposis, surgery, infection. any respiratory disease, other than mild asthma or seasonal allergic rhinitis participated in another clinical study within 30 days. Subject has donated a unit of blood within 1 month Use of prescription or nonprescription drugs, including vitamins and st john's wort within 7 days of trial. History of sensitivty to drug History of alcohol/drug abuse within 12 months. Positive Hepatitis B antibody test Positive HIV antibody test Risk of noncompliance with study protocol Perenial allergic rhinitis Administration of oral, injectable or dermal corticosteriods within 8 weeks, intranasal or inhaled within 3 weeks. Past or present disease that may affect outcome, as judge by investigator Specific Immunotherapy within 2 years</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Proof-of-Concept</keyword>
	<keyword>Allergic Rhinitis</keyword>
</DOC>